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For patients with Relapsing Remitting Multiple Scierosis Beta Interfaerons and Glatiramer Acetate were the ﬁrst to be licensed for
treatment. This review deals with one major question: when to initiate therapy? Through exploring the unique characteristics of
the disease and treatement we suggest an approach that should be helpful in the process of decision-making.
1.Introduction
Until the early nineties, the major challenge for Multiple
Sclerosis (MS) neurologists was to establish the diagno-
sis when a patient presents clinical picture suggestive of
MS. Treating MS patients consisted mainly of education,
supportive measures, and symptomatic treatments. MS
appeared as an unmodiﬁable illness with many stories of
disappointment when using immunosuppressant therapy.
When beta-Interferons (IFNs) and Glatiramer Acetate (GA)
were introduced, and vigorously marketed, into the world
of MS, patients’ and neurologists’ prospective about MS
changed and focus in management shifted. Now, experts in
MS around the globe strive to best answer the question that
appears with every newly diagnosed patient: when to start
treatment with Disease-Modifying Drugs (DMDs)? Which
drug to use?
This review deals with the former question. We will
address the second question in a later review. Despite
the absence of class I recommendations, we support the
worldwide trend towards early treatment. We explore the
possible reasons behind this consensus. We also address
the implications of starting treatment early, and how one
could explain the reluctance of some MS patients to start
DMDs despite these medications being partly or completely
supported by health beneﬁts in numerous countries. We
review these treatments in Relapsing Remitting MS (RRMS),
since as we discuss in this paper, IFNs and GA were licensed
for this disease phenotype. Eﬃcacy was not shown for
Primary Progressive MS (PPMS). We conclude by detailing
our approach to the question of when to start, and we
emphasize the importance of individualizing this decision to
the patient’s circumstances.
In this review we focus on IFNs and GA as they are ﬁrst-
line treatments and widely available. We will not review in
detail when to start Mitoxantrone or Natalizumab. Suﬃce
it to say that we exceptionally use them as ﬁrst-line when
Relapsing Remitting MS (RRMS) appears to be rapidly lead-
ing to disability. Fingolimod has not been commercialized
long enough that its place in the armamentarium against MS
can yet be determined.
2. When to Start DMDs? Why Is It
a Matterof Debate?
2.1. Characteristics of the Disease. In this section we discuss
the features of MS that makes it a challenging disease. MS
is mysterious for its true onset in individual patients, and
thus talking about early versus late treatment remains to be a
relative rather than an absolute argument. Here, we start by
brieﬂy exploring the diﬃculties that may face a neurologist2 Multiple Sclerosis International
diagnosing MS and prognosticating its path in individual
patients.
2.1.1.TheComplexityofMakingaDiagnosis ofMS. Although
patients may present with a highly suggestive clinical picture
(typicalagegroup and symptoms) supported by a brainMRI
that fulﬁll the widely accepted Barkhof’s criteria [1], many
times the diagnosis is not straight forward. In the absence of
a perfect marker, the diagnosis of MS should only be made
after fulﬁlling the criteria of dissemination in place and time
(McDonald Criteria) [2], and actively ruling out mimickers.
It follows that delays in initiating treatment may result from
waiting for a second clinical attack. The introduction of MRI
to the routine practice of MS neurology paved the road for
a new concept, Clinically Isolated Syndrome (CIS), or “ﬁrst
demyelinating event suggestive of MS”. With the ability to
actually “see” the disease before it fully manifest clinically
the concept of treating before fulﬁlling diagnostic criteria
emerged. One problem is that although an abnormal MRI
places a patient with a CIS at high risk to develop further
attacks,therewillremainanumberofpatientswhowillnever
develop MS. Racing with time, some neurologists will repeat
the MRI after a few months, as MRI is known to be more
sensitive to disease activity than clinical relapses [3]. This
could hasten the establishment of the diagnosis and allow a
more conﬁdent approach to early treatment.
2.1.2. Prognosis of MS Cannot Be Predicted in Individual
Patients. One of the most puzzling aspects of MS is its
great variability in terms of natural course. A considerable
percentage of 15–20% of MS patients will continue to
mobilize freely and live independently throughout their lives
without treatment [4] .T h eg r e a tc h a l l e n g ei st ob ea b l et o
tell who will and who will not run a benign course. Eighty
percent of patients who present with a clinically isolated
syndrome (CIS) and who have abnormal MRI brain, will
convert to clinically deﬁnite MS (CDMS), and most do so
within the two years of initial presentation [5]. MRI brain
has proved to be so far the most useful tool in determining
thelikelihoodofconversioninthisclinicalscenario.However
it remains impossible to predict disease progression on the
long-term at this stage, and may remains so even after 10
years from disease onset [6].
Most recent studies, however, suggest that the disease
course during the ﬁrst few years after clinical onset, and
before the Expanded Disability Status Scale (EDSS) reaches
a score of 3 to 4, is the most relevant in terms of predicting
disability progression. In their natural history study of 806
essentially untreated MS patients, Scalfari et al. [7]s h o w e d
thattherewasacorrelationbetweenthefrequencyofrelapses
during the ﬁrst two years ofthe relapsing phase ofthe disease
and the time to development of EDSS scores 6, 8, and 10.
This correlation was absent for relapse frequency at any time
after two years from clinical onset (deﬁned as the date of
the ﬁrst symptom). These results came in accordance with
those of another recent study by Leray and colleagues [8].
These studiesagree with earlier ones ofConfavreux et al. and
Debouverie et al. [9, 10] demonstrating that the number of
relapses wasno longera predictoroffuture disabilityoncean
EDSS score of 4 was reached.
On the other hand, there remains no consensus on the
deﬁnition of benign MS. While it is usually deﬁned based
on a long duration (longer than 15 years) and a low score
of EDSS (no cutoﬀ point has been agreed upon yet), it is
important to keep in mind that EDSS scoring system does
not parallel functionality, productivity, or quality of life.
EDSS does not account for highly prevalent and disabling
symptoms in MS like fatigue, depression, cognitive decline,
and pain [11].
In an attempt to better understand benign MS and
to reach a better deﬁnition for this disease phenotype,
Rovaris et al. [12]r e v i e w e dt h ed i ﬀerences in MRI ﬁndings
between two groups of RRMS patients, those who fulﬁlled
the current deﬁnition of benign MS according to disease
duration and EDDS score and those who did not. There
were no diﬀerences between the two groups in the number
of T2 lesions. However MRI brain of patients with benign
MSshowedrelativesparingofeloquentareas,relativesparing
of the cortex and of the infratentorial structures, less severe
damage inside the macroscopic lesions and less diﬀuse
damage outside these lesions. Interestingly functional MRI
(fMRI) studies showed altered patterns of cortical activation
and network connectivity in benign MS that may represent
a compensatory mechanism through cortical reorganization.
The authors explained how these diﬀerences may help in
understanding benign MS and emphasized the importance
of excluding cognitive decline when deﬁning this phenotype,
since there was evidence of more gray matter damage shown
by magnetization transfer and fMRI in patients with benign
MS and cognitive decline [13].
2.1.3. What Is “Early” in MS. An important fact in MS is
that the disease process starts several years prior to clinical
presentation, if not very early in life. The epidemiological
studies, particularly on the migrant populations, strongly
suggest that a number of environmental factors may start
their eﬀect on genetically susceptible individuals very early
in life, if not before birth [14].
This proposal is ampliﬁed by the ﬁnding of a high
percentage of abnormal conventional brain MRIs in patients
w i t hC I Sw h oc o n v e r tt oC D M S[ 15, 16], the discovery of
abnormalitiesinvisualevokedpotentialsinCISpatientswith
and without history of optic neuritis [17], and the presence
of cognitive decline in the very early stages of MS in patients
with minimal locomotor disability and even in patients with
CIS[18–20].Inaddition,itisquitefrequentthatCISpatients
will later recall past events that might have represented
ﬁrst clinical manifestation of MS. An interesting case report
by McDonnell et al. describes a patient who clinically
manifested PPMS a whole 10 years after an abnormal MRI
brain. This patientserved asa “normal control” in a study on
Parkinson’s disease when he had the MRI brain study [21].
Advanced MRI studies reveal several changes at the very
earliest stages of MS or in patients with CIS undetected by
conventional MRI [22–31]. Even before T2 Lesions appear,
a special appearance of the white matter has been described:
the dirty appearing white matter [32].Multiple Sclerosis International 3
2.1.4. When Is “Too Late” in MS. Sometimes one encounters
patients years after the clinical onset of the disease, and
the question of starting a DMD at this stage can be
equally challenging. Two questions to consider here. The
ﬁrst is, would DMDs retain their eﬃcacy even when started
later during the relapsing remitting stage of MS? In other
words, would the therapeutic window for DMDs within
the relapsing remitting stage of the disease remain open
as long as there are relapses and/or Gadolinium enhancing
lesions, and probably closes when the progressive phase
(without relapses) is reached? As clinicalstudies proved IFNs
and GA to be much less eﬀective in secondary progressive
MS (SPMS) [33], the second question would then be,
when would a patient be doomed to enter the secondary
progressive stage?
Most MS patients included in the pivotal IFNs and GA
trialshadadiseasedurationofoneyearormore;inonestudy
disease duration of 6 months was allowed and in another,
disease duration had to be of more than 3 years. Otherwise,
disease duration was not an exclusion criterion except in one
study when patients were excluded if they had MS for more
than 15 years. Patients however were excluded if they had an
EDSS score of more than 5.5 or 6, and in one study when
EDSS was more than 3.5 [34–36]. On the other hand, in the
BENEFIT trial on patients with clinically isolated syndrome
(CIS), it has been demonstrated that patients who started oﬀ
in the treatment arm did better than those who were crossed
over to the treatment arm [37]. That was also demonstrated
for RRMS patients included in PRISMS cross-over study
[38], and in the GA US-based study [39].
Summary. A diagnosis of MS has to be made cautiously for
itslife-long implications. Itisa stigma in thecommunityand
aﬀects every aspect of life, including personal relationships,
employment, and medical insurance. Tools for forecasting
prognosis are lacking, and the natural course of illness is
very variable. Disease behavior during the ﬁrst two years and
MRI changes early in the disease hold promise as ways of
speculating the course of MS.
In order to tell about the true onset of MS, brain MRIs
may need to be done on at-risk populations at a very
young age (e.g., oﬀspring of aﬀected parents in areas of high
prevalence of MS), however may remain very diﬃcult to
know without a biological or genetic marker for MS.
2.2. Characteristics of the Treatment (IFNs and GA). Until
recently, IFNs and GA were the only approved treatment for
MS and remain the best studied to date. Despite the growing
trend towards earlier treatment, DMDs will not be always
instituted as soon as a diagnosis is made, or anticipated as
in CIS. In order to understand why, we review the eﬀectsand
limitations of the currently available DMDs, their safety, and
the evidence supporting starting treatment after a CIS in the
following section.
2.2.1. DMDs in MS: Eﬀectiveness and Cost-Eﬀectiveness
(1) Eﬀects on Relapses and Conversion to SPMS. In ran-
domised clinical trials (RCTs) eﬃcacy of DMDs in RRMS
was measured based on their eﬀect on relapses frequency
and severity, eﬀect on MRI parameters (number of new T2
lesions, T2 lesions load, lesions enhancement, brain atrophy,
etc.), and eﬀect on conﬁrmed changes in EDSS. In studies
on patients with CIS the primary focus was the time to
conversion to CDMS.
The pivotal studies that lead to licensing of IFNs and
GA were heterogeneous to some extent and diﬃcult to
compare. Each had its own strengths and limitations. In
the literature there is a considerable number of reviews and
meta-analyses, interestingly with variable and sometimes
conﬂicting conclusions, depending on the weight given by
each author or reviewer to certain points of weakness or
limitation, the time when the analysis was done (before or
after other studies or open label extensions were completed),
and probably personal experience.
In general, one can say that all currently available IFN
preparations and GA proved superior to placebo in terms of
eﬀect on frequency of relapses in RRMS patients. In the piv-
otal trials [40–44], they all reduced the frequency of relapses
to a similar degree, almost 30% compared to placebo group
[39, 44–46]. The protective eﬀect of the IFNs and the GA
on relapses was recognized during the ﬁrst year of treatment.
Critiques argued that this eﬀect was no more present for GA
and couldnotbeconﬁrmedforIFNs,duringthesecondyear.
For IFNs, the reason was the high number of dropouts and
the failure to do an intention-to-treat analysis [45].
On the other hand, open label studies for both agents,
despite all the inherent limitations of this study design,
suggest a sustained beneﬁt for these DMDs on relapse fre-
quency. It is however expected in MS patients to have fewer
relapses as the disease duration increases, when degenerative
changes override inﬂammatory events. It is also diﬃcult to
make absolute conclusions from these studies due to the
fact that only a proportion of patients who were initially
included continued to follow up. One may wonder if the
patientswho didnotenterthefollow upactuallyfared worse.
Propensity to bias due to loss of randomization may render
the trials less representative of the natural history of RRMS.
Moreover, patients may have not been monitored, may have
discontinued the drug for considerable amount of time,
switched to another DMD, or added another one [47, 48].
In additionto the eﬀect onrelapse rate, open label exten-
sions of the original studies and nonrandomised retrospec-
tive studies showed delayed time to conversion to SPMS and
to reaching high EDSS scores in the treated group [47–50].
Although these nonrandomised prospective or retrospective
studies carry less weight in evidence-based medicine because
of the reasons discussed, the fact that they all go in the same
direction would be takenas an evidence.Howeverthe energy
ofthepharmaceuticalindustry supportingthemmaydeprive
them of this very relative advantage.
(2) Eﬀects on MRI Parameters. The eﬀects of the IFNs
and GA on MRI parameters in the pivotal trials in MS
was even more robust than the clinical eﬀect, and further
supported their role in managing MS. Studies, including
those which followed the pivotal trials, suggest sustained
eﬀectsondiseasesburdenasseenonMRI.Afavourableeﬀect4 Multiple Sclerosis International
was demonstrated on the number of enhancing lesions, rate
of black holes formation, as well as on the rate of brain
atrophy [51–54]. Importantly, an inverse correlation was
found between T1 hypointense and T2 hyperintense lesions,
and the absolute change in brain volume over 6 years [54],
and there was a signiﬁcant correlation between the changes
inT1hypointenselesionsfrombaselinetoyear2andchanges
in supratentorial brain volume from year 2 to 6.
The relation between the rate of brain atrophy and the
subsequentdevelopmentofdisabilitywaswell-demonstrated
by Fisher et al. in an 8-year follow up study for the patients
originally involved in a phase III IFN-1a trial [55]. In this
study, the percent change of brain parenchymal fraction
(BPF) over two years correlated with both EDSS and MS
functional composite (MSFC) at 8 years. This makes the
eﬀect of DMDs on brain atrophy clinically relevant, and
indicates that the rate of brain atrophy could be considered a
surrogate marker for predicting disability progression. Inter-
estingly, however, there was no diﬀerence in BPF and BPF
percent change at follow up, between the group of patients
who were originally randomised to receive treatment versus
the group who was not. In other words there was no corre-
lation between the BPF and the BPF percent change, and the
total time on DMD from baseline to the 8-year follow up.
In a small open-label, single-blinded study, a positive
eﬀect of IFN-1a on the gray matter fraction (GMF) but not
white matter fraction (WMF) after a follow up period of
3 years was suggested. This ﬁnding may indicate diﬀerent
dynamics and mechanisms behind white matter and gray
matter atrophy in MS, and that the favorable DMD eﬀect
on brain atrophy might be mainly through reducing GMF
atrophy [56] .T h ei m p o r t a n c eo fg r a ym a t t e ra t r o p h ya n d
its correlation to disability particularly measured by MSFC
was demonstrated by Rudick et al., who followed 70 patients
and compared them to 17 healthy controls (HCs) over an
average period of time of 6.6 years [57]. Based on the results
of this study, the authors suggest that EDSSis less sensitive in
more disabled patients with more brain atrophy than MSFC,
and propose that MSFC correlates better with pathology
than EDSS does. In another study, cervical cord atrophy
was also found to be associated with disability measured by
EDSS and MSFC, independently from gray matter atrophy
[58].
(3) The Ultimate Goal: Eﬀects on Disability
(i) Disability as Measured by EDSS. Although it is desirable
to have less and milder relapses during the course of MS,
the ultimate goal of DMDs therapy in MS remains to be
preventing, or at least delaying, the progression of disability.
A recent meta-analysis by Sormani et al. [59]s h o w e d
that there is a signiﬁcant correlation between the eﬀect of
treatment on relapse rate, emergence of new MRI lesions,
and conﬁrmed EDSS progression. This ﬁnding supports
the use of EDSS as an endpoint in clinical trials in MS,
particularly that there was a strong correlation between the
EDSS changes during the ﬁrst two years of randomization to
a phase III IFN trial, and the likelihood of reaching clinically
important EDSS scores 8 years after randomization [60].
(ii) Cognitive Disability. Another important aspect of mea-
suring the eﬃcacy of DMDs is through their eﬀect on
cognition and fatigue; two major sources of disability which
are not captured by EDSS. An eﬀect of DMDs on cognitive
decline can be inferred from the fact that they may reduce
brain atrophy, particularly their eﬀect on gray matter, as
discussed above. However it is certainly more convincing
to look at the studies that compared DMDs-treated and
untreated MS patients in relation to the degree of cognitive
impairment.
Pliskin et al. [61] was among the ﬁrst to study the
eﬀectsofIFN-1bon cognitionin MSpatients. Delayedvisual
reproduction test performance improved in the subgroup of
patients who were treated with high dose IFN-1b. The study
was done on a total of 30 MS patients originally randomised
to receive high dose, low dose, or no IFN-1b treatment, as
part of the pivotal IFN-1b trial.
However, Montalban and Rio [62], through reviewing
6 studies on the eﬀect of DMDs on cognition (1996–2003)
including Pliskin’s, concluded that the eﬀects of DMDs on
cognition is not clear and the results are inconclusive, and
that more studies need to be conducted.
The only pivotal IFN study that incorporated neuropsy-
chological testing was that for Avonex [63]. The results
suggest signiﬁcant eﬀect of Avonex injections on cognitive
function, particularly domains measured by PASAT. Only
few studies were published more recently on the eﬀect of
the IFN preparations on cognition; none were randomised
double-blinded placebo-controlled trials [64, 65]. Limited
conclusions can be made out of the results of these studies.
Same holds true for GA. More than 10 years ago,
Weinstein and colleagues [66] performed the ﬁrst large-scale
study on the eﬀect of a DMD on cognitive function in MS.
Cognitive performance rather improved in both the placebo
and the treated group at 1 and 2 years follow up. Moreover,
cognitive function at baseline was largely intact at baseline in
both groups. The authors concluded that GA did not show
ap r o t e c t i v ee ﬀect on cognition, and this could be due to a
number of reasons, including lack of signiﬁcant impairment
at base line, short follow up period and lack of deterioration
in boththetreatedand thecontrolgroup,and insensitivity of
the testing tools to changes occurring over two years in this
population of patients. No studies dedicated to test the eﬀect
of GA on cognition were published thereafter, and it remains
unclear if GA can prevent cognitive decline.
(iii) Eﬀects on Fatigue. As we pointed out earlier in this
review, fatigue is one of the most debilitating symptoms in
MS, even in patients with low EDSS scores, and it aﬀects
quality of life and employment. A major problem with
fatigue is that surrounding people with limited knowledge
about MS may not appreciate the impact ofthis symptom on
the ability to work. Fatigue is one major aspect of MS that
could beneﬁt from treatment with DMDs. A good number
of studies looked at the correlation between brain atrophy
and fatigue. The importance of this correlation relies in
the fact that DMDs may actually prevent brain atrophy, as
discussed above. From there one can infer that DMD may
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the rate or degree of brain atrophy. Studies, however, did not
agree as whether or not fatigue can be correlated with MRI
brain measures like lesion load or brain atrophy. Bakshi et
al. [67], studied 71 consecutive RRMS and SPMS patients.
They looked at correlations between fatigue as measured by
the Fatigue Severity Scale, and some of the conventional
MRI brain parameters including lesions load, degree of
focal or global brain atrophy, and presence of lesions in the
brainstem. They could not ﬁnd a correlation between fatigue
and these MRI parameters. This is in accordance with what
Werf et al. found in his study of 45 patients with RRMS and
SPMS [68].
On the other hand, a number of recently published
studies did show an evidence for an association between
brain atrophy in MRI and fatigue [69–72], and in some of
them,itwasmostlythegraymatteratrophythatwasfoundto
becorrelated,particularly thedeepgraynucleiandthecortex
of the parietal lobe.
There are no placebo-controlled studies on the eﬀect of
DMDs on fatigue in MS patients. In his observational study,
Ziemssen et al. [73] found that GA treatment ameliorated
fatigue and reduced the number of days taken oﬀ work,
when a comparison was made between the 3 months prior
to starting treatment and the last three months of follow
up after initiating treatment (total observational period of
12 months). As the authors indicated there is a number
of limitations to this study, including weaknesses inherent
in this study design, particularly absence of a comparative
group. In a cross-sectional study, the investigators could
not demonstrate diﬀerences in fatigue prevalence or severity
between treated and treated MS patients [74]. Treatment
included a variety of DMDs and immunosuppressant medi-
cations.
(4)Cost-Eﬀectiveness. There is a number ofstudiesthatdealt
with the economic impact of multiple sclerosis by looking
at the direct and indirect costs of the disease, and how do
DMDs contribute to the total ﬁnancial burden.
Directs costs of MS are the medical costs including
payments made to healthcare providers for inpatients and
outpatient care, physical therapy, rehabilitation, laboratory
services, drugs, and so forth, Indirect costs are those related
to loss of productivity and loss of Quality of Life (QOL).
It became obvious through the results of these studies
that the more advanced the disease the higher are the costs,
and that the indirect costs of the disease are the major
contributor to the cost of illness in MS [75]. Indirect costs
increase in proportion with the loss of QOL, and the latter
seems to improve with Interferon treatment [76].
The evaluation of DMDs cost-eﬀectiveness was for the
majorpartdonethroughcross-sectional studyofdirectcosts,
the so called Economic Modeling Studies. Cost-eﬀectiveness
was tested through measuring cost per quality adjusted
year life (QALY). Studies were heterogeneous in many ways
and diﬃcult to compare. Parkin et al. [77] concluded that
treatment with IFN-1b did not produce long-term gains in
QALYs. So did Phillips in a review study [78].
Other economic studies reached diﬀerent conclusions in
regard tocost-eﬀectivenessoftreatmentwithIFNs,including
fortreatmentafterCIS[79,80].Thesestudieswerefundedby
the manufacturing companies.
The uncertainty around the cost-eﬀectiveness of DMDs
reﬂect the complexity of measuring this endpoint, and
the high variability of study design prevented us from
reaching a deﬁnite conclusion. Detournay [81] discusses
the limitations and diﬃculties of the economic modeling
studies in evaluating DMDs cost-eﬀectiveness, not only in
performing them, but also in understanding them.
2.2.2. Safety of DMDs. I F N sa n dG Ah a v eb e e ni nu s ef o r
about 20 years. They proved to be safe and well-tolerated.
Adverse events from the use of IFNs and GA may be
divided in to three major categories.
(1) Common but non life-threatening side eﬀects,
mainly ﬂu-like symptoms with IFNs injection, and
subcutaneous adipose tissue necrosis with GA injec-
tions. Despite being referred to as “benign side
eﬀects”,ﬂu-likesymptoms andinjectionsitereactions
are recognized as major factors in impaired adher-
ence to treatment, as we discuss below.
( 2 )R a r eb u ts e r i o u ss i d ee ﬀects: fulminant liver failure
and skin necrosis, with the use of IFNs and GA
respectively.
(3) The emergence of NAB during the course of treat-
ment with IFNs.
A recently published cross-sectional study, although
insensitive to rare side eﬀects, proved long-term safety of
IFN-1b for RRMS after a 16-year follow up [82]. In an open-
label extension study of the phase III trial of intramuscular
IFN-1a, patients who received treatment for 6-8 years were
assessed for immunogenicity and safety [83]. Again the
drug proved safe and well-tolerable. The rates of depression
were found similar to those in the general MS populations.
However dedicated studies looking at correlation between
treatment with IFNs and depression in terms of incidence
andseverityneedtobeconductedbeforedeﬁniteconclusions
can be drawn. Miller et al. [49] evaluated a small number of
patients who were treated with GA for a median duration
of 12 years (range 1–22 years) in an open-label design. GA
was shown to be safe and well-tolerable. No patients in this
cohort of 46 developed skin necrosis.
Two recent prospective studies on a small number of
patients [84, 85] suggested that treatment with GA or IFNs
might be safe during pregnancy. In one study [84]n i n e
patients were exposed to GA for the whole period of preg-
nancy.However,theremightbeincreased riskofmiscarriage,
spontaneous abortions, and low birth weight. Moreover
it remains to be discovered the long-term developmental
adverse events in exposed foetuses.
2.2.3. Treatment after CIS. The current literature abounds
in studies and analyses supporting the initiation of DMDs
early in RRMS or even after the ﬁrst demyelinating event
suggestive of MS (CIS) [5, 9, 10, 33, 37, 59, 86–88].
This may represent a global trend [33, 89–93]t o w a r d s
earlier treatment in the hope of preventing irreversible6 Multiple Sclerosis International
damage. It may also represent the eﬀects of relentless
and vigorous eﬀorts from the manufacturing companies,
and probably as well patients and media pressure to “do
something”forayoungpopulationwithpotentiallydisabling
illness.
However, this trend is justiﬁed by the available evidence.
As discussed above, the characteristics of the disease (MS)
and the characteristics of the treatment (IFNs and GA)
support the use of DMDs after the CIS. Goodin and Bates
[5] list a number of facts in favour of a decision of treatment
after CIS.
(1) Evidence of axonal injury early on in the disease [94,
95]: axonal injury was present even in the absence
of disability and progressed more rapidly during the
earlier stages of the disease.
(2) Evidence of brain atrophy at the earliest stages of the
disease; higher rate of atrophy occurred in RRMS,
compared to SPMS [55, 96–98].
(3) In CIS patients, the number of lesions at baseline
MRI, and the increase in lesion volume over the ﬁrst
5 years, both correlated with EDSS at 14 years [99].
(4) Treatment with IFNs or with GA delayed conversion
to CDMS. In addition, larger treatment eﬀects were
obtained when treatment was started in the CIS stage
than when started in the RRMS stage, and larger
when started in the RRMS stage than when started
in the SPMS [41, 42, 100–109].
Summary. Collectively, IFNs and GA are eﬀective in modi-
fying the natural course of MS through their partial, albeit
signiﬁcant, impact on relapse frequency, disease burden on
MRI, and time to sustained disability. Their impact on
other aspects on MS particularly disabling symptoms like
fatigue and cognitive impairment remains to be conﬁrmed.
The inherently limited studies on cost-eﬀectiveness support
their use, and postmarketing surveillance proved their safety.
The rationale behind starting treatment as early as after
a CIS suggestive of MS and supported by abnormal MRI
brain seems to be well-supported by a growing number of
clinical and pathological studies, however other important
considerations, as discussed below, argue against starting
treatmentafteraCISineverysinglepatient,andthusstarting
early cannot be considered as a standard of care.
2.3. Implications of Starting Treatment Early
2.3.1. Long-Term Commitment and Adherence. MS is a
chronic disorder, and it is not yet known when it is ideal
to stop DMDs once started. Patients knowing this about
their treatment may reduce their tolerance to what we, as
physicians, identify as minor side eﬀects, and may impair
long-term adherence. Starting DMDs after a CIScould mean
starting during early to mid-twenties, when a patient is
busiest studying or working, with many plans and dreams
on board. For women of child-bearing age, the decision to
start a DMDs might well be aﬀected by or aﬀect their plans
to conceive, and that should be taken in consideration too.
Treatment discontinuation ranges from 14 to 44% in
long-term postmarketing studies of IFNs [110]. The most
common reasons for discontinuation were side eﬀects (most
commonly injection-site reactions and ﬂu-like symptoms)
and unrealistic expectations of IFNs treatment. Tremlett
and Oger [111] found that the number one reason for
interruption of IFNs therapy was perceived lack of eﬃcacy.
Twenty-ﬁve percent of patients taking DMDs (IFNs or
GA) were found nonadherent to treatment, according to
the results of the Global Adherent Project [112]. In this
study, the two most common reasons for nonadherence
were: forgetting to take the injections and injection site
reactions.
2.3.2. Neutralizing Antibodies (NABs) to IFNs. There is yet
no global consensus on the clinical signiﬁcance of the
development of NABs in MS patients treated with IFNs.
However a panel of European experts believe that NABs
aﬀect the clinical eﬃcacy of IFNs, and they recommended a
set of actions to be taken depending on how well the patient
is doing clinically [113].
Many factors contribute to the emergence of NABs
including the formula of the IFN used, route of administra-
tion, dose and frequency [114]. NABs do not persist in every
patient, with patients with higher titers being more likely to
have persistently positive testing to NABs.
Developing NABs early during the disease course, as in
the case of starting treatment after a CIS, may have diﬀerent
eﬀects on treatment success than when NABs develop later.
Indeed this has not being studied before, but is worth
considering when deciding about initiating treatment early.
2.3.3. Participation in Ongoing or Future Clinical Trials.
Being on one of the current DMDs may deprive the patient
from the chance to participate in clinical trials testing new
treatments in MS, or may delay his or her entry to the
study. It also means that it will be more diﬃcult to form
a control group to which treated patients can be compared
prospectively or retrospectively.
2.4. How to Answer the Question “When” in the Clinic. In a
patient with a single demyelinating event suggestive of MS,
the decision of whether to treat or not and when to start
a DMD has to be made by mutual agreement between the
treating neurologist and his/her patient. In order to optimize
adherence and achieve maximum beneﬁt from treatment,
a patient must be well-informed, contribute to decision
making, be comfortable with the decisions made, and be
willing to commit.
2.4.1. Acknowledge Patients’ Diﬀerences in Attitude towards
Treatment. Ross [115] discussed the importance of knowing
what attitude does a patient hold towards treatment. There
are 4 groups of patients: treatment-believers, treatment-
suspicious, treatment-seekers, and treatment-disheartened.
Discussion has to be tailored accordingly. Because adherence
is a goal in treatment, the answer to when to start a DMDMultiple Sclerosis International 7
may vary between these groups of patients, even for those
with very similar disease characteristics.
2.4.2. Patients Need to Be “Well Informed”. The patients
should be made aware of the limitations of the current treat-
ment options. Realistic goals need to be set, and the patients
should learn that this is not a “symptomatic” treatment.
Having relapses does not necessarily indicate treatment
failure. Side eﬀects need to be addressed and strategies
to decrease their frequency, intensity, and impact on their
lives should be taught. Patients’ personal circumstances may
prevent them from starting treatment at a certain point of
time, when they cannot handle extra stress in their lives. For
the sake of optimizing adherence, it could be wise therefore
to wait till after patients are more capable of handling
all the diﬃculties around starting a new treatment. If the
diﬀerent companies have setup support services for MS
patients starting on DMDs, it is our deep-felt conviction
that these companies cannot do as good a job as the MS
clinic nurse who already knows the patient, his/her personal
circumtances, character and approach to life. This nurse
should be the person in direct contact with the patient to
help him/her to make the appropriate decision as to when
and what to use as a DMD.
Patients will ask about newly emerging therapies. The
eﬀects on being on one of the current ﬁrst-line DMD prior
to starting treatment with one of the newer agent are not yet
known. The possible impact on the response to treatment
with the newer agent or on development of side eﬀects with
the newer treatment is not known as well.
2.4.3. Local Policies and Healthcare System. Finally, in an
ideal world, ﬁnancial limitations should not play a major
role when it comes to making decisions about treatment.
However an ideal world does not exist. A neurologist’s deci-
sion will be frequently inﬂuenced by the health care system
regulations. Free medical care is not available everywhere. In
certain areas, certain treatments are not available to every
patient, depending on a number of factors including the
type of insurance they hold, the rules and regulation of
the country or province where they live, and the type of
disease they have. The Helsinki accord which has not been
signed by all DMD companies, call for trials not to take
place in the countries where the drug will not be available
for patients post trial. Unfortunately the number of these
countries has been increasing rather than decreasing. We
hope this will convince big Pharma to make the drugs more
availableratherthancontinuetheraceforthemostexpensive
products.
3.Conclusion
After considering all the diﬀerent factors discussed in this
review, our answer to the question When to Start Treatment
remains highly individualized. Our reading of the literature
onlypartlysupportsearly treatment afterclinicalonsetofthe
multiple sclerosis. We do not think that delaying treatment
by a few months after the onset of a CIS impacts the long-
term prognosis.
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